Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.43 |
| ▸ | CNR2 | P34972 | 8/20 | 0.42 |
| ▸ | RORC | P51449 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 3/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.41 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4069812 | 0.89 | MEN1 (0.41) | PKMPIK3C3CNR2RORCCNR1 | |
| SCHEMBL4070531 | 0.86 | CNR2 (0.38) | PKMPIK3C3CNR2CNR1RIOK2 | |
| SCHEMBL1464740 | 0.85 | CNR2 (0.58) | PKMPIK3C3CNR2RORCCNR1 | |
| SCHEMBL1463731 | 0.84 | AR (0.52) | PIK3C3CNR2RORCCNR1 | |
| SCHEMBL1464642 | 0.78 | CNR2 (0.54) | PIK3C3CNR2CNR1 | |
| SCHEMBL1463707 | 0.78 | RAB9A (0.52) | CNR2CNR1 | |
| SCHEMBL1464429 | 0.77 | PKM (0.53) | PKMPIK3C3CNR2RORCCNR1 | |
| SCHEMBL12671876 | 0.77 | PKM (0.65) | PKMCNR2RORCCNR1NR3C2 | |
| SCHEMBL1464488 | 0.76 | PKM (0.49) | PKMCNR2RORCCNR1NR3C2 | |
| SCHEMBL1464325 | 0.76 | CNR2 (0.54) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081905-B1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2012-09-12 | — | — | EP | claimed |
| US-7935715-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-03 | — | — | US | claimed |
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | US | claimed |
| US-8299111-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| US-8299111-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| US-8299111-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| EP-2081905-B1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2012-09-12 | — | — | EP | disclosed |
| US-7935715-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-03 | — | — | US | disclosed |
| US-7935715-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-03 | — | — | US | disclosed |
| US-7935715-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-03 | — | — | US | disclosed |
| US-20110071127-A1 | Compounds Which Modulate the CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20110071127-A1 | Compounds Which Modulate the CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20110071127-A1 | Compounds Which Modulate the CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | PKM 3811/4885PIK3C3 4357/4885CNR2 1/4885 |
| US-20110071127-A1 | Compounds Which Modulate the CB2 Receptor | CNR2, CNR1, OPRL1 | PKM 3736/4885PIK3C3 4368/4885CNR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.